Tissue heterogeneity of EGFR mutation in lung adenocarcinoma

Journal of Thoracic Oncology

Volumn 3, Issue 5, 2008, Pages 527-529

  Sakurada, Akira ^a   Lara Guerra, Humberto ^a   Liu, Ni ^a   Shepherd, Frances A ^b   Tsao, Ming Sound ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Epidermal growth factor receptor; Heterogeneity; Mutation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 43049132516     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318168be93     Document Type: Article

References (16)

1. A Sakurada FA Shepherd MS Tsao Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations Clin Lung Cancer 7 Suppl 4 2006 S138 44
2. TJ Lynch DW Bell R Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
3. W Pao VA Miller Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions J Clin Oncol 23 2005 2556 2568
4. DA Eberhard BE Johnson LC Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
5. DW Bell TJ Lynch SM Haserlat Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 2005 8081 8092
6. MS Tsao A Sakurada JC Cutz Erlotinib in lung cancer—molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
7. RS Herbst D Prager R Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
8. H Iwamatsu K Nishikura H Watanabe Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma Gastric Cancer 4 2001 20 26
9. CA Klein TJ Blankenstein O Schmidt-Kittler Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer Lancet 360 2002 683 689
10. M Kitago M Ueda K Aiura Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas Int J Cancer 110 2004 177 182
11. Q Pan W Pao M Ladanyi Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas J Mol Diagn 7 2005 396 403
12. Y Nagai H Miyazawa Huqun Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp Cancer Res 65 2005 7276 7282
13. Y Yoshida T Shibata A Kokubu Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung Lung Cancer 50 2005 1 8
14. X Tang H Shigematsu BN Bekele EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients Cancer Res 65 2005 7568 7572
15. W Pao VA Miller KA Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.[see comment] PLoS Med 2 2005 e73
16. PA Jänne AM Borras YA Kuang A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening Clin Cancer Res 12 2006 751 758